Hualan Biological Bacterin Inc.
Hualan Biological Vaccine Inc. engages in the research and development, production, and sale of vaccines and genetic engineering biological products in China. The company offers influenza vaccine (split virion), recombinant hepatitis B vaccine (hansenula polymorpha), meningococcal polysaccharide vaccine, influenza vaccine (split virion) quadrivalent, and meningococcal polysaccharide vaccine. It a… Read more
Hualan Biological Bacterin Inc. (301207) - Net Assets
Latest net assets as of September 2025: CN¥5.67 Billion CNY
Based on the latest financial reports, Hualan Biological Bacterin Inc. (301207) has net assets worth CN¥5.67 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.18 Billion) and total liabilities (CN¥1.50 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.67 Billion |
| % of Total Assets | 79.04% |
| Annual Growth Rate | 38.44% |
| 5-Year Change | 174.93% |
| 10-Year Change | N/A |
| Growth Volatility | 31.53 |
Hualan Biological Bacterin Inc. - Net Assets Trend (2017–2024)
This chart illustrates how Hualan Biological Bacterin Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hualan Biological Bacterin Inc. (2017–2024)
The table below shows the annual net assets of Hualan Biological Bacterin Inc. from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥6.01 Billion | -3.99% |
| 2023-12-31 | CN¥6.26 Billion | +13.95% |
| 2022-12-31 | CN¥5.50 Billion | +95.74% |
| 2021-12-31 | CN¥2.81 Billion | +28.39% |
| 2020-12-31 | CN¥2.19 Billion | +73.28% |
| 2019-12-31 | CN¥1.26 Billion | +42.31% |
| 2018-12-31 | CN¥886.93 Million | +43.80% |
| 2017-12-31 | CN¥616.78 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hualan Biological Bacterin Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 388.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.29 Billion | 38.12% |
| Common Stock | CN¥601.03 Million | 10.00% |
| Other Comprehensive Income | CN¥327.37 Million | 5.44% |
| Other Components | CN¥2.79 Billion | 46.44% |
| Total Equity | CN¥6.01 Billion | 100.00% |
Hualan Biological Bacterin Inc. Competitors by Market Cap
The table below lists competitors of Hualan Biological Bacterin Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Easttop Supply Chain Management Co Ltd
SHE:002889
|
$208.61 Million |
|
Yamashin-Filter Corp
PINK:YMFCF
|
$208.68 Million |
|
Tyro Payments Ltd
AU:TYR
|
$208.71 Million |
|
Chongqing Yukaifa Co Ltd
SHE:000514
|
$208.71 Million |
|
Qingdao Hi-Tech Moulds & Plastics Technology Co. Ltd.
SHE:301022
|
$208.53 Million |
|
Shanghai Prosolar Resources Development Co Ltd
SHG:600193
|
$208.52 Million |
|
Neogen Chemicals Limited
NSE:NEOGEN
|
$208.51 Million |
|
Road Environment Technology Co. Ltd. A
SHG:688156
|
$208.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hualan Biological Bacterin Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,263,091,926 to 6,013,144,521, a change of -249,947,405 (-4.0%).
- Net income of 205,515,314 contributed positively to equity growth.
- Dividend payments of 334,316,500 reduced retained earnings.
- Share repurchases of 106,786,852 reduced equity.
- Other comprehensive income increased equity by 327,371,306.
- Other factors decreased equity by 341,730,673.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥205.52 Million | +3.42% |
| Dividends Paid | CN¥334.32 Million | -5.56% |
| Share Repurchases | CN¥106.79 Million | -1.78% |
| Other Comprehensive Income | CN¥327.37 Million | +5.44% |
| Other Changes | CN¥-341.73 Million | -5.68% |
| Total Change | CN¥- | -3.99% |
Book Value vs Market Value Analysis
This analysis compares Hualan Biological Bacterin Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.92x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 16.94x to 1.92x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥1.14 | CN¥19.35 | x |
| 2018-12-31 | CN¥1.64 | CN¥19.35 | x |
| 2019-12-31 | CN¥2.10 | CN¥19.35 | x |
| 2020-12-31 | CN¥3.65 | CN¥19.35 | x |
| 2021-12-31 | CN¥4.68 | CN¥19.35 | x |
| 2022-12-31 | CN¥9.16 | CN¥19.35 | x |
| 2023-12-31 | CN¥10.40 | CN¥19.35 | x |
| 2024-12-31 | CN¥10.05 | CN¥19.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hualan Biological Bacterin Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.22%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 1.25x
- Recent ROE (3.42%) is below the historical average (17.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -12.47% | -26.98% | 0.34x | 1.37x | CN¥-138.56 Million |
| 2018 | 30.46% | 33.65% | 0.59x | 1.54x | CN¥181.46 Million |
| 2019 | 29.73% | 35.78% | 0.58x | 1.42x | CN¥249.08 Million |
| 2020 | 42.29% | 38.12% | 0.67x | 1.67x | CN¥706.20 Million |
| 2021 | 22.11% | 33.94% | 0.40x | 1.61x | CN¥340.16 Million |
| 2022 | 9.45% | 28.46% | 0.26x | 1.29x | CN¥-30.02 Million |
| 2023 | 13.73% | 35.68% | 0.30x | 1.28x | CN¥233.66 Million |
| 2024 | 3.42% | 18.22% | 0.15x | 1.25x | CN¥-395.80 Million |
Industry Comparison
This section compares Hualan Biological Bacterin Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hualan Biological Bacterin Inc. (301207) | CN¥5.67 Billion | -12.47% | 0.27x | $208.60 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |